Browsing by Author Estell, Jane

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2017Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practiceCunningham, Ilona; Curnow, Jennifer; Estell, Jane; Foo, Kerwyn; Gasiorowski, Robin Edward; Lee, Kenneth; Trotman, Judith; Archer, K; Bianchi, Alessandra; Fletcher, Julie; Kwan, Yiu Lam; Siedlecka, E; Trinh, Jimmy; Verner, Emma; Wignall, L; Concord Clinical School: Medicine; Clinical Schools; Concord Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: Medicine; Concord Clinical School: MedicineFormalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice, Internal Medicine Journal, vol.47, 5, 2017,pp 542-548
2011Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants.Estell, Jane; Fulham, Michael; Trotman, Judith; Decaudin, Didier; et al, various; Fabiani, Bettina; Forsyth, Cecily; Fournier, Marion; Gabarre, Jean; Gyan, Emmanuel; Janíkova, Andrea; Lamy, Thierry; Salles, Bruno; Seymour, John Francis; Shpilberg, Ofer; Sonet, Anne; Tilly, Hervé; Concord Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: MedicinePositron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants., Journal of Clinical Oncology, vol.29, 23, 2011,pp 3194-3200
2011Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trialEstell, Jane; Belada, David; Bouabdallah, Réda; Brice, Pauline; Catalano, John Vincent; et al, various; Feugier, Pierre; López-Guillermo, Armando; Offner, Fritz; Salles, Gilles; Seymour, John F.; Xerri, Luc; Concord Clinical School: MedicineRituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, The Lancet, vol.377, 9759, 2011,pp 42-51